ADVERTISEMENT

404

Not Found

Is this what you were looking for?

tag intellectual property genetics genomics microbiology

Tumor microbiome composite
Could Cancer’s Microbiome Help Diagnose and Treat the Disease?
Jef Akst | Mar 14, 2022 | 10+ min read
A growing appreciation of the bacterial assemblages that live within tumors has researchers striving to understand and capitalize on their role.
Toward a “Clickable Plant”
Jane Salodof Macneil | Feb 15, 2004 | 9 min read
By conscious design, plant genomics initiatives have devoted initial resources to new technology development. Part of that money went to developing functional genomics approaches, and part to new sequencing technologies.
Sequencing Stakes: Celera Genomics Carves Its Niche
Ricki Lewis | Jul 18, 1999 | 8 min read
J. Craig Venter is no stranger to contradiction and controversy. He seems to thrive on it. In 1991, when the National Institutes of Health was haggling over patenting expressed sequence tags (ESTs)--a shortcut to identifying protein-encoding genes--Venter the inventor accepted a private offer to found The Institute for Genomic Research (TIGR) in Rockville, Md. TIGR would discover ESTs and give most of them to a commercial sibling, Human Genome Sciences (HGS), to market. ESTs are now a standard
Alfred Pühler
Cormac Sheridan | Jan 12, 2009 | 3 min read
Alfred Pühler Forty years (and counting) at the forefront of microbiology research have not dimmed Pühler's infectious enthusiasm or voracious work ethic. By Cormac Sheridan Alfred Pühler has been a powerhouse in German microbiological research—initially in the area of plant-microbe interactions and later in industrial microbiology—over the past four decades. But he actually started out in nuclear physics, obtain
Top 7 in Immunology
Edyta Zielinska | Aug 2, 2011 | 3 min read
A snapshot of the most highly ranked articles in microbiology and related areas, from Faculty of 1000
Will Genomics Spoil Gene Ownership?
Douglas Steinberg | Sep 3, 2000 | 8 min read
Consider a scenario for the year 2002: Using commercially available software, bioprospector "Craig Collins" spends a day scavenging the Human Genome Project (HGP) database for the alternatively spliced genes prized by Wall Street. He enters the sequences of several candidate genes into a software package that prints out the likely functions of their protein products. One protein looks like it could be pharmaceutical paydirt, so he isolates the corresponding cDNA, inserts it into a vector, then
University Bargains with Students' Rights
Karen Young Kreeger | Nov 11, 2001 | 5 min read
Three years ago, the University of California, Berkeley, plant and microbial biology (PMB) department negotiated an exclusive research relationship with Novartis Agricultural Research Institute that allowed the company to review graduate student and postdoc work before publication. But the university didn't consult the students before trading away their intellectual property rights, provoking lasting anger and confusion, according to a sociologist's report commissioned by the university. Many
Influential Consortium's cDNA Clones Praised As Genome Research Time-Saver
Karen Young Kreeger | May 14, 1995 | 7 min read
IMAGE group's DNA libraries are made freely available to other researchers, as long as they, too, pass on information to the public. In less than two years, a research initiative begun by four geneticists has grown from an ad hoc collaboration to an international cooperative effort to freely share complementary DNA (cDNA) clone libraries. To date, in excess of 100,000 clones from the Integrated Molecular Analysis of Genome Expression (IMAGE) Consortium have been sent to more than 40 facilities
Single Nucleotide Polymorphisms: Big Pharma Hedges its Bets
Eugene Russo | Jul 18, 1999 | 7 min read
SNP CENTRAL: A genetics researcher takes to the bench at the Wellcome Trust's Sanger Centre in Cambridge, England. The sequencing center and its London sponsor provided key leadership in the SNP Consortium, a public-private venture to find and map 300,000 single nucleotide polymorphisms. The Wellcome Trust helped entice 10 pharmaceutical firms to join the consortium by putting up $14 million of the project's estimated $45 million price tag. The Sanger Centre will provide much of the radiation h
Clinton, Blair Stoke Debate on Gene Data
Ricki Lewis | Apr 2, 2000 | 7 min read
President Bill Clinton and British Prime Minister Tony Blair's brief statement of March 14 supporting free access to human genome information unleashed a slew of clichés, including "too little too late" and "water under the bridge." But initial misinterpretation of the statement led to a temporary slide in biotech stocks. By the end of the day, Celera Genomics Corp. of Rockville, Md., had dropped 19 percent, while Incyte Pharmaceuticals of Palo Alto, Calif., plummeted 27 percent. Even thoug

Run a Search

ADVERTISEMENT